lapatinib has been researched along with Hepatocellular Carcinoma in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Tan, J; Xu, M; Zhong, Z | 1 |
| Austin, E; Kalomeris, T; Larimer, B; Mahmood, U; Nesti, S; Sinevici, N; Wehrenberg-Klee, E | 1 |
| Chen, JY; Chen, YJ; Chien, PH; Huang, WC; Wei, CT | 1 |
| Chen, YJ; Chi, CW; Huang, HL; Su, WC | 1 |
| Chen, JY; Chen, WS; Chen, YJ; Huang, WC; Yen, CJ | 1 |
| Belani, CP; Dancey, J; Gandara, DR; Gandour-Edwards, R; Iqbal, S; Kindler, HL; Lenz, HJ; Longmate, J; Lurje, G; Mack, PC; Ramanathan, RK; Singh, DA; Tanaka, M; Yen, Y | 1 |
| Balint, C; Bekaii-Saab, T; Campbell, A; Chen, H; Culler, K; Dai, Z; Dancey, J; Eng, C; Grever, M; Heerema, N; Lee, RM; Markowitz, J; O'Neil, B; Papp, A; Prescott, N; Sadee, W; Villalona-Calero, M; Wei, L; Zalupski, M | 1 |
2 trial(s) available for lapatinib and Hepatocellular Carcinoma
| Article | Year |
|---|---|
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Humans; Lapatinib; Liver Neoplasms; Quinazolines; Survival Analysis | 2009 |
A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Predictive Value of Tests; Quinazolines; Survival Rate | 2009 |
5 other study(ies) available for lapatinib and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Identification of an Oxidative Stress-Related LncRNA Signature for Predicting Prognosis and Chemotherapy in Patients With Hepatocellular Carcinoma.
Topics: Biomarkers, Tumor; Carcinoma, Hepatocellular; Dasatinib; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Liver Neoplasms; Oxidative Stress; Prognosis; RNA, Long Noncoding; Sorafenib | 2022 |
HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Liver Neoplasms; Mice; Positron-Emission Tomography; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Tissue Distribution | 2021 |
The
Topics: Antiviral Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hepatitis B virus; Humans; Lapatinib; Liver Neoplasms; Peptides; Protein Domains; Receptor, ErbB-3; Trans-Activators; Up-Regulation; Viral Regulatory and Accessory Proteins | 2019 |
Lapatinib induces autophagic cell death and inhibits growth of human hepatocellular carcinoma.
Topics: Animals; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Autophagy-Related Protein 7; Beclin-1; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Immunoblotting; Lapatinib; Liver Neoplasms; Membrane Proteins; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Transmission; Microtubule-Associated Proteins; Mitochondria; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Tumor Burden; Ubiquitin-Activating Enzymes; Xenograft Model Antitumor Assays | 2014 |
HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3.
Topics: Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Survival; ErbB Receptors; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Hepatitis B virus; Humans; Lapatinib; Liver Neoplasms; NF-kappa B; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Trans-Activators; Up-Regulation; Viral Regulatory and Accessory Proteins | 2016 |